Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India

Background At the peak of the coronavirus disease 2019 (COVID-19) pandemic, the need for an orally administered agent to prevent the progression of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection became increasingly evident, which was the impetus behind our investigations with molnup...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Shubhadeep, N, Kumarasamy, Suram, Vasanth Kumar, Chary, Sreenivasa S, Naik, Sunil, Singh, Veer Bahadur, Jain, Manish K, Suthar, Chandra P, Borthakur, Swapnav, Sawardekar, Vinayak, Sk, Noushadali, Reddy, Naveen, Talluri, Leela, Thakur, Pankaj, Reddy, Mohan, Panapakam, Muralidhar, Vattipalli, Ramya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751243/
https://www.ncbi.nlm.nih.gov/pubmed/36532902
http://dx.doi.org/10.7759/cureus.31508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751243/
https://www.ncbi.nlm.nih.gov/pubmed/36532902
http://dx.doi.org/10.7759/cureus.31508

Ejemplares similares